Retension Pharmaceuticals, Inc.

What the company does

Retension Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its lead product candidate, RTN-001, is a once-daily, oral, small molecule PDE-5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling. The company is developing RTN-001 for uncontrolled hypertension and resistant hypertension.

Use of proceeds

We intend to use the net proceeds of this offering, together with our existing cash and cash equivalents to complete the Phase 2b clinical trial and prepare for, support and advance the planned Phase 3 clinical trial of RTN-001 in uHTN and the remainder for general corporate purposes and other operating expenses.

Underwriters

Extracted from 424B4 0001213900-26-108587, filed Oct 9, 2026 and verified against that filing text.

Key risk factors

• Going concern doubt

  “Our recurring losses from operations and financial condition raise substantial doubt about our ability to continue as a going concern and the report of our independent registered public accounting firm on our financial statements as of and for the fiscal year ended December 31, 2025 includes an explanatory paragraph indicating that there is substantial doubt about our ability to continue as a going concern.”

• Dependence on RTN-001

  “We currently depend entirely on the success of RTN-001, which is our only product candidate.”

• Need for additional capital

  “We will require substantial additional capital to finance our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations.”

• Material weakness in controls

  “We have identified a material weakness in our internal control over financial reporting. Failure to remediate such material weakness or maintain effective internal controls could cause our investors to lose confidence in us and adversely affect the market price of our common stock.”

• Restatement of financials

  “We recently identified and corrected certain accounting errors in our previously issued financial statements, resulting in the restatement of our consolidated financial statements as of and for the fiscal year ended December 31, 2025.”

• Immediate dilution

  “Purchasers of common stock in this offering will experience immediate dilution of approximately $5.75 per share, based on the initial public offering price of $12.00 per share.”

• Insider control

  “After this offering, our executive officers, directors and principal stockholders, if they choose to act together, will continue to have the ability to significantly influence all matters submitted to stockholders for approval and may prevent new investors from influencing significant corporate decisions.”

• Related-party conflicts

  “We have entered into transactions with entities controlled by some of our officers and directors, which could pose a conflict of interest.”